3-甲硫基芬太尼 | 86052-04-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲硫基芬太尼
• 英文名称: 3-Methylthiofentanyl
• 英文别名: N-[3-methyl-1-(2-thiophen-2-ylethyl)piperidin-4-yl]-N-phenylpropanamide
• CAS: 86052-04-2
• 化学式: C₂₁H₂₈N₂OS
• 分子量: 356.5
• InChiKey: SRARDYUHGVMEQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] AN OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION<br/>[FR] OPIOÏDE DESTINÉ À ÊTRE UTILISÉ POUR RÉDUIRE ET/OU TRAITER LA PHARMACODÉPENDANCE
  申请人：VERSI GROUP LLC

  公开号：WO2018204163A1

  公开（公告）日：2018-11-08

  The present invention relates to a method of treating drug addiction and reducing dependence or tolerance on a dependence-inducing opiate drug, wherein the method comprises administering to a subject a compound having the structure of formula (I): having the IUPAC name of (-)3-((S)-((2S,5R)-4-allyl-2,5-dimethyl-l-piperazinyl)(3-thienyl)methyl)phenol, or pharmaceutically acceptable esters or salts thereof, wherein the compound has activity on the mu, delta and kappa opioid receptors thereby providing added analgesia with an improved therapeutic index and reduced risk of respiratory depression.

  本发明涉及一种治疗药物成瘾、减少对诱导依赖的鸦片类药物的依赖或耐受性的方法，其中该方法包括向受试者施用具有以下公式（I）结构的化合物：(-)3-((S)-((2S,5R)-4-烯丙基-2,5-二甲基-1-哌嗪基)(3-噻吩基)甲基)苯酚的IUPAC名称，或其药学上可接受的酯或盐，化合物对mu、delta和kappa阿片受体具有活性，从而提供具有改善的治疗指数和减少呼吸抑制风险的附加镇痛作用。
• [EN] COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS<br/>[FR] FORMULATIONS SALINES DE COMPOSÉS PHARMACEUTIQUES À BASE D'AGENTS COMPLEXANTS
  申请人：BEXSON BIOMEDICAL INC

  公开号：WO2022109050A1

  公开（公告）日：2022-05-27

  Provided herein are pharmaceutical formulations and pharmaceutical compound salts which utilize complexing agents as counterions. Such formulations and salts are useful for treating a variety of disease and disorders.

  本文提供了药物制剂和药物化合物盐，其使用络合剂作为反离子。这些制剂和盐对治疗各种疾病和障碍有用。
• Controlled release formulation with continuous efficacy
  申请人：Egalet Ltd.

  公开号：EP2700400A1

  公开（公告）日：2014-02-26

  The present invention relates to pharmaceutical compositions, which provide controlled release of a drug. The compositions are suitable for continuous administration as they remain effective throughout the treatment regimen. The present invention also relates to the use of the compositions for preparation of a medicament for continuous treatment of an individual.

  本发明涉及可控制药物释放的药物组合物。这些组合物适合连续给药，因为它们在整个治疗过程中都能保持有效。本发明还涉及使用这些组合物制备用于对个人进行连续治疗的药物。
• PHARMACEUTICAL COMPOSITION PROVIDED WITH ABUSE-PREVENTION FUNCTION
  申请人：Daiichi Sankyo Co., Ltd.

  公开号：EP3175845A1

  公开（公告）日：2017-06-07

  An object of the present invention is to provide a pharmaceutical composition having abuse deterrent properties and thereby prevent the abuse of a pharmacologically active component by an abuser (abuse through snorting, abuse through injection, or abuse through snorting or injection of a temporarily extracted drug). The present invention provides a pharmaceutical composition having abuse deterrent properties that possesses both a physical barrier and a chemical barrier to being abused by an abuser, a method for producing the same and a method for using the same.

  本发明的目的是提供一种具有阻止滥用特性的药物组合物，从而防止药理活性成分被滥用者滥用（通过吸食滥用、通过注射滥用或通过吸食或注射临时提取的药物滥用）。本发明提供了一种具有阻止滥用特性的药物组合物，这种组合物具有物理屏障和化学屏障，可防止滥用者滥用，还提供了一种生产这种组合物的方法和一种使用这种组合物的方法。
• Nasal drug products and methods of their use
  申请人：Adapt Pharma Limited

  公开号：US10085937B2

  公开（公告）日：2018-10-02

  Drug products adapted for nasal delivery, comprising a pre-primed device filled with a pharmaceutical composition comprising an opioid receptor antagonist, are provided. Methods of treating opioid overdose or its symptoms with the inventive drug products are also provided.

  本发明提供了适用于鼻腔给药的药物产品，该产品包括一个装有阿片受体拮抗剂药物组合物的预填充装置。本发明还提供了使用本发明药物产品治疗阿片类药物过量或其症状的方法。